Browse the corpus

Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.

• Aetiology of fever of unknown origin in people living with HIV: A systematic review and meta-analysis1 passage
• Comorbidities in women living with HIV: A systematic review1 passage
• Comparison of treatment-emergent resistance-associated mutations and discontinuation due to adverse events among integrase strand transfer inhibitor-based single-tablet regimens and cabotegravir + rilpivirine for the treatment of virologically suppressed people with HIV: A systematic literature review and network meta-analysis1 passage
• Diabetes risk in HIV infection and antiretroviral therapy: A systematic review and meta-analysis of prospective cohort evidence1 passage
• Exploring the impact of baseline and on-treatment variables on durability of responses to fostemsavir through weeks 96 and 192 in the phase 3 BRIGHTE study1 passage
• Free antiretrovirals as a key tool against the HIV pandemic: A systematic review1 passage
• HIV/AIDS post-exposure prophylaxis knowledge and uptake among health professionals in Africa: Systematic review and meta-analysis1 passage
• Major revision version 11.0 of the European AIDS Clinical Society Guidelines 20211 passage
• Major revision version 13.0 of the European AIDS Clinical Society guidelines 20251 passage
• Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life1 passage
• Plasma sVCAM-1, antiretroviral therapy and mortality in HIV-1-infected West African adults1 passage
• Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials1 passage
• Transitions in treatment: A systematic review and meta-aggregation of preferences and barriers in switching from oral to long-acting injectable antiretroviral therapy among people living with HIV and stakeholders1 passage